Processa Pharmaceuticals 過去の業績

過去基準チェック /06

Processa Pharmaceuticals は平均年間 11.2% の収益成長を遂げていますが、Pharmaceuticals 業界では年間収益成長率となっています。9.1% です。

主要情報

11.25%

収益成長率

49.07%

EPS成長率

Pharmaceuticals 業界の成長	5.95%
収益成長率	n/a
株主資本利益率	-555.19%
ネット・マージン	n/a
前回の決算情報	31 Mar 2026

Recent updates

分析記事 • Dec 12

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

分析記事 • Oct 20

Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Aug 12

Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73

Processa Pharmaceuticals press release (NASDAQ:PCSA): Q2 GAAP EPS of $0.53 beats by $0.73. Company cash balance on June 30, 2022, was $12.1 million,

分析記事 • Jul 07

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

分析記事 • Jan 20

We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

分析記事 • Aug 26

Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

分析記事 • Mar 15

What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?

The big shareholder groups in Processa Pharmaceuticals, Inc. ( NASDAQ:PCSA ) have power over the company. Institutions...

分析記事 • Jan 20

How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...

収支内訳

Processa Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:PCSA 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
31 Mar 26	-14	6	8
31 Dec 25	-14	6	8
30 Sep 25	-13	6	7
30 Jun 25	-13	5	8
31 Mar 25	-12	5	7
31 Dec 24	-12	5	7
30 Sep 24	-12	5	7
30 Jun 24	-10	5	6
31 Mar 24	-10	4	6
31 Dec 23	-11	6	6
30 Sep 23	-22	7	8
30 Jun 23	-26	9	10
31 Mar 23	-28	10	11
31 Dec 22	-27	9	11
30 Sep 22	-18	7	10
30 Jun 22	-15	6	9
31 Mar 22	-13	5	7
31 Dec 21	-11	5	7
30 Sep 21	-23	5	7
30 Jun 21	-23	4	5
31 Mar 21	-20	3	4
31 Dec 20	-19	3	3
30 Sep 20	-6	2	2
30 Jun 20	-4	2	2
31 Mar 20	-4	2	2
31 Dec 19	-4	2	2
30 Sep 19	-3	1	2
30 Jun 19	-3	1	2
31 Mar 19	-3	1	3
31 Dec 18	-4	1	3
30 Sep 18	-4	1	3
30 Jun 18	-4	1	3
31 Mar 18	-3	1	2
31 Dec 17	-2	1	1
31 Dec 16	-2	0	2

質の高い収益: PCSAは現在利益が出ていません。

利益率の向上: PCSAは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: PCSAは利益を出していないが、過去 5 年間で年間11.2%の割合で損失を削減してきた。

成長の加速: PCSAの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: PCSAは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -5% ) と比較することは困難です。

株主資本利益率

高いROE: PCSAは現在利益が出ていないため、自己資本利益率 ( -555.19% ) はマイナスです。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/05/15 09:06
終値	2026/05/15 00:00
収益	2026/03/31
年間収益	2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Processa Pharmaceuticals, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。4

アナリスト	機関
Robin Garner Kalley	Craig-Hallum Capital Group LLC
Raghuram Selvaraju	H.C. Wainwright & Co.
Nazibur Rahman	Maxim Group

Processa Pharmaceuticals 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Recent updates

Processa Pharmaceuticals, Inc. Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study

Processa Pharmaceuticals, Inc. Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer

New major risk - Market cap size

New minor risk - Profitability

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 Pcs499 Study in Fsgs At Asn Kidney Week 2025

Processa Pharmaceuticals Receives Notice from Nasdaq Regarding the Bid Price Requirement Compliance

Processa Pharmaceuticals, Inc. announced that it has received $1.257452 million in funding

Processa Pharmaceuticals, Inc. Provides Updates on its Product Pipeline

New major risk - Share price stability

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $7 million.

New major risk - Financial position

Processa Pharmaceuticals, Inc., Annual General Meeting, Jun 30, 2025

Processa Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Bid Price Requirement

Processa Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.999298 million.

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Processa Pharmaceuticals, Inc. Provides Updates on its Product Pipeline

Processa Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Processa Pharmaceuticals, Inc. Announces Positive Preclinical Data for NGC-IRI

New major risk - Financial position

Processa Pharmaceuticals, Inc. Announces FDA Clearance of IND Application for A Phase 2 Clinical Trial of NGC-Cap in Breast Cancer

Processa Pharmaceuticals, Inc. Announces CFO Changes

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million.

Processa Pharmaceuticals, Inc., Annual General Meeting, Jun 28, 2024

Processa Pharmaceuticals, Inc. Names Steven Cha as Senior Vice President of Clinical Research

Processa Pharmaceuticals, Inc. Presents Two Abstracts At the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1B Trial

New major risk - Shareholder dilution

Co-Founder recently bought US$51k worth of stock

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Processa Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $6.99989 million.

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $7 million.

Processa Pharmaceuticals, Inc. Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety over Capecitabine

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Processa Pharmaceuticals, Inc. Provides Data Update Supporting A Potential Personalized Treatment Approach for Improved Cancer Care

Processa Pharmaceuticals, Inc. Appoints George Ng as Chief Executive Officer

New major risk - Share price stability

New major risk - Market cap size

Processa Pharmaceuticals, Inc. Announces to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial

High number of new and inexperienced directors

Processa Pharmaceuticals, Inc. Announces Positive Gastric Emptying Results from its Pcs12852 Phase 2A Trial in Patients

Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial

Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

Processa Pharmaceuticals, Inc. Provides Update on Enrollment Across All Clinical Programs

Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73

High number of new and inexperienced directors

Processa Pharmaceuticals, Inc. Announces Board Changes

Processa Pharmaceuticals, Inc. Elects Khoso Baluch as Director

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Processa Pharmaceuticals, Inc., Annual General Meeting, Jul 11, 2022

Price target decreased to US$15.00

Processa Pharmaceuticals, Inc. Doses First Patient in Amended Phase 1B Protocol for Pcs6422 Combined with Capecitabine

Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis

We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate

Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans

Processa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer

Co-Founder recently bought US$77k worth of stock

Processa Pharmaceuticals, Inc. Announces First Patient Dosed in Its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

Processa Pharmaceuticals, Inc. Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica

What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?

Processa Pharmaceuticals, Inc. announced that it has received $10.238773 million in funding

New 90-day high: US$10.89

Processa Pharmaceuticals, Inc. announced that it expects to receive $10.238773 million in funding

How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?

Processa Pharmaceuticals, Inc. Announces Executive Changes

Processa Pharmaceuticals, Inc. Appoints R. Michael Floyd as Chief Operating Officer

Co-Founder recently bought US$125k worth of stock

Processa Pharmaceuticals, Inc. has completed an IPO in the amount of $19.2 million.

New 90-day low: US$3.95

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

過去基準チェック /06